Moffitt Presentations at ASCO 2025
Note - all times are listed as CT
-
Saturday May 31, 2025
9 a.m.
Hall A
Poster
4101 / L:391 Survival outcomes for zanidatamab-hrii compared to chemotherapy in previously treated HER2- positive (IHC3+) biliary tract cancer (BTC): HERIZON- BTC-01 vs a real-world (RW) external control arm (ECA).
1:27 p.m.
Arie Crown Theater
Rapid Oral
4515 Zanzalintinib (zanza) + nivolumab (nivo) ± relatlimab (rela) in patients (pts) with previously untreated clear cell renal cell carcinoma (ccRCC): Results from an expansion cohort of the phase 1b STELLAR-002 study.
1:30 p.m.
Hall A
Poster
11123 / L: 462 Quality of life in a phase III study of prospective radiation therapy (IMRT) +/- cetuximab for locally advanced resected head and neck cancer: NRG/RTOG 0920.
1:30 p.m.
Hall A
Poster
11105 / L:444 Understanding psychosocial wellbeing and concern for death and dying: Insights from a psycho-oncology clinic.
Shahrzad Zamani
1:30 p.m.
Hall A
Poster
TPS8659 / L:133a Phase 2, multicenter study of frontline maintenance therapy with lifileucel plus pembrolizumab in advanced non-small cell lung cancer.
5:36 p.m.
Hall D2
Oral
Walking the Tightrope of Targets and Toxicities (Abstract Discussant)
-
Sunday June 1, 2025
8-11 a.m.
Arie Crown Theater
Oral Session / Chair
Lung Cancer—Non-Small Cell Metastatic
Bruna Pellini (Session Chair)
9 a.m.
Hall A
Poster
1534 / L:287 APP-first as a strategy to increase new patient access and treatment of patients with gastrointestinal malignancies within a cancer center.
9 a.m.
Hall A
Poster
5536 / L:434 Atezolizumab and stereotactic body radiation in metastatic, recurrent, or persistent cervical cancer: Results from a phase II multi-institutional study.
9 a.m.
Hall A
Poster
7552 / L:120 Impact of autoimmune disease on toxicity and outcomes after idecabtagene vicleucel in patients with multiple myeloma.
Rebecca Albuquerque
9 a.m.
Hall A
Poster
TPS9603 / L:80b Multicenter, randomized, double-blinded, placebo-controlled trial of IFx-Hu2.0 (IFx) as adjunctive therapy with pembrolizumab (pembro) in checkpoint
inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC).
9 a.m.
Hall A
Poster
9545 / L:28 Progression-free survival (PFS) assessment by blinded independent central review (BICR) versus local investigator (LI) in metastatic melanoma (MM) randomized controlled trials (RCT): A systematic review and meta-analysis.
Islam Eljilany
9 a.m.
Hall A
Poster
9535 / L:18 Clinical and biomarker analyses of first-line nivolumab and relatlimab (nivo-rela) in advanced or resectable melanoma (mel).
9 a.m.
Hall A
Poster
6569 / L:185 E ect of prior treatment (tx) on the clinical activity of imetelstat (IME) in transfusion-dependent (TD) patients (pts) with erythropoiesis-stimulating agent (ESA), relapsed or refractory (R/R)/ineligible lower-risk myelodysplastic syndromes (LR-MDS).
9 a.m.
Hall A
Poster
6576 / L:192 E cacy and safety outcomes of obecabtagene autoleucel (obe-cel) stratified by age in patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
12:12 p.m.
E450a
Rapid Oral
6017 Ficerafusp alfa with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: Updated results from an expansion cohort of an open-label, multicenter, phase 1/1b trial.
2:09 p.m.
Hall B1
Plenary
LBA3 Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment o polycythemia vera (PV).
4:30 p.m.
E451
Educational
Early Complications of Immunotherapies
Michael David
-
Monday June 2, 2025
8-9 a.m.
S102
Cased-based Panel
Multidisciplinary Treatment of Anaplastic Thyroid Cancer
Caitlin McMullen (panelist)
9 a.m.
Hall A
Poster
598 / L:191 Long-term outcomes in triple-negative breast cancers (TNBC) treated with talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy (NACT).
9 a.m.
Hall A
Poster
TPS1132 / L:105a Immunologic targeting of native and mutated ESR1 receptor for treatment of hormone receptor expressing metastatic breast cancer.
9 a.m.
Hall A
Poster
1057 / L:36 Results of a phase 1 study of vosilasarm (EP0062), a first-in-class oral selective androgen receptor modulator (SARM) in patients with advanced or metastatic AR+/ER+/HER-2- breast cancer.
9 a.m.
Hall A
Poster
TPS1141 / L:109b Emiltatug ledadotin (Emi-Le): A B7-H4-directed dolasynthen antibody-drug conjugate (ADC) being investigated in phase 1 dose expansion in patients with triple negative breast cancer who received at least one prior topoisomarase-1 inhibitor ADC.
9 a.m.
Hall A
Poster
TPS6110 / L:517b A phase II study of ACR-368 and low dose gemcitabine combination therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.a.
Robin Park
10:27 a.m.
E451
Rapid Oral
9514 A phase II study of neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma.
10:27 a.m.
E350
Rapid Oral
9008 Recognizing international medical graduates: Awards and committe membership in ASCO.
Karun Neupane
10:51 a.m.
E451
Rapid Oral
9516 Infusion product characteristics to predict response to tumor-infiltrating lymphocyte (TIL) therapy in metastatic melanoma (MM).
1:15 p.m.
Arie Crown Theater
Cased-based Panel
Navigating Emerging Therapeutic Decisions in the Treatment of Small Cell Lung Cancer: Cases and Considerations
Sonam Puri (moderator)
1:30 p.m.
Hall A
Poster
12021/ 41 DNA methylation biomarkers of cardiotoxicity risk in breast cancer patients treated with anthracyclines.
1:30 p.m.
Hall A
Poster
TPS2677 / L:319b Logic-gated, allogeneic Tmod chimeric antigen receptor T-cell (CAR T) therapy targeting epidermal growth factor receptor (EGFR) in advanced solid tumors with human leukocyte antigen (HLA) loss of heterozygosity (LOH): DENALI-1 trial.
1:30 p.m.
Hall A
Poster
2540 / L:187 Mayhem under the microscope: T cell cytotoxicity and serial killers captured in situ.
-
Tuesday June 3, 2025
9:45 a.m.
S100bc
Oral
Hematologic Malignancies—Plasma Cell Dyscrasia (Discussant Moderator)
11:09 a.m.
S100a
Oral
LBA9505 A phase II randomized study of neoadjuvant pembrolizumab (P) alone or in combination with vidutolimod (V) in high-risk resectable melanoma: ECOG-ACRIN EA6194.
11:57 a.m.
S100a
Oral
LBA9507 A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab
+ nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT04511013).